CN104603108A - 哌啶鎓季盐 - Google Patents

哌啶鎓季盐 Download PDF

Info

Publication number
CN104603108A
CN104603108A CN201380042085.3A CN201380042085A CN104603108A CN 104603108 A CN104603108 A CN 104603108A CN 201380042085 A CN201380042085 A CN 201380042085A CN 104603108 A CN104603108 A CN 104603108A
Authority
CN
China
Prior art keywords
methyl
alkyl
propoxy
piperidinium
phenylbenzene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380042085.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·E·克拉伦斯-史密斯
T·N·蔡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Priority to CN201810664740.3A priority Critical patent/CN108658842A/zh
Publication of CN104603108A publication Critical patent/CN104603108A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
CN201380042085.3A 2012-08-09 2013-07-30 哌啶鎓季盐 Pending CN104603108A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810664740.3A CN108658842A (zh) 2012-08-09 2013-07-30 哌啶鎓季盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
US61/681,415 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810664740.3A Division CN108658842A (zh) 2012-08-09 2013-07-30 哌啶鎓季盐

Publications (1)

Publication Number Publication Date
CN104603108A true CN104603108A (zh) 2015-05-06

Family

ID=50068488

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810664740.3A Pending CN108658842A (zh) 2012-08-09 2013-07-30 哌啶鎓季盐
CN201380042085.3A Pending CN104603108A (zh) 2012-08-09 2013-07-30 哌啶鎓季盐

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810664740.3A Pending CN108658842A (zh) 2012-08-09 2013-07-30 哌啶鎓季盐

Country Status (14)

Country Link
US (1) US9896416B2 (enExample)
EP (1) EP2882711B1 (enExample)
JP (1) JP6345665B2 (enExample)
KR (2) KR20150040355A (enExample)
CN (2) CN108658842A (enExample)
AU (1) AU2013300009B2 (enExample)
BR (1) BR112015002832B1 (enExample)
CA (1) CA2881182C (enExample)
EA (1) EA029678B9 (enExample)
HK (1) HK1211572A1 (enExample)
IL (1) IL236996A0 (enExample)
IN (1) IN2015DN01018A (enExample)
MX (1) MX356386B (enExample)
WO (1) WO2014025569A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265128A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
EP3324966A4 (en) * 2015-07-20 2019-04-10 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION OF A SELECTIVE M2 ANTAGONIST AND A PERIPHERAL NON-ELECTECTIVE ANTAGONIST FOR THE TREATMENT OF HYPOCHOLINERGEN DISORDERS
CN114868435B (zh) 2019-08-22 2023-12-26 欧芬诺有限责任公司 针对多址接入的策略控制
CN117018194A (zh) * 2023-07-26 2023-11-10 同济大学 毒蕈碱型受体5型受体拮抗剂的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (enExample) * 1973-07-12 1974-06-20
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
WO2011114195A1 (en) * 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
DE10129832A1 (de) 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
AU2006279572A1 (en) * 2005-08-12 2007-02-22 The Government Of The United States Of America, As Represented By The Secretary Neuronal avalanche assay
SE0600876L (sv) 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
US20090233965A1 (en) * 2006-04-24 2009-09-17 Astrazeneca Ab Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
IN2015DN01706A (enExample) * 2012-09-05 2015-05-22 Chase Pharmaceuticals Corp

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (enExample) * 1973-07-12 1974-06-20
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
WO2011114195A1 (en) * 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGISTRY: "RN 101202-60-2", 《STN COLUMBUS》 *
WILLIAM P. JENCKS， ET AL.: "Decreasing Reactivity with Increasing Nucleophile Basicity. The Effect of Solvation on βnuc for Phosphoryl Transfer to Amines", 《JOURNAL OF AMERICAN CHEMICAL SOCIETY》 *

Also Published As

Publication number Publication date
BR112015002832B1 (pt) 2022-08-16
AU2013300009B2 (en) 2017-06-15
US20150203452A1 (en) 2015-07-23
KR20150040355A (ko) 2015-04-14
EA201500209A1 (ru) 2015-05-29
HK1211572A1 (en) 2016-05-27
JP6345665B2 (ja) 2018-06-20
BR112015002832A2 (enExample) 2017-07-04
CA2881182A1 (en) 2014-02-13
CA2881182C (en) 2021-01-26
JP2015524469A (ja) 2015-08-24
MX356386B (es) 2018-05-28
AU2013300009A1 (en) 2015-02-26
IL236996A0 (en) 2015-03-31
EP2882711A4 (en) 2016-02-10
US9896416B2 (en) 2018-02-20
WO2014025569A1 (en) 2014-02-13
EP2882711B1 (en) 2017-10-25
EA029678B9 (ru) 2018-07-31
EP2882711A1 (en) 2015-06-17
KR102240999B1 (ko) 2021-04-15
KR20200022522A (ko) 2020-03-03
CN108658842A (zh) 2018-10-16
MX2015001769A (es) 2015-05-08
EA029678B1 (ru) 2018-04-30
IN2015DN01018A (enExample) 2015-06-26

Similar Documents

Publication Publication Date Title
TW200306830A (en) N-[phenyl (piperidin-2-yl) methyl] benzamide derivatives, their preparation and their application in therapy
JP2003516391A (ja) ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物
EP1513826A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
WO2023087611A1 (zh) 一类依巴斯汀的盐及其制备方法和应用
CN104603108A (zh) 哌啶鎓季盐
CN109734614B (zh) 3-羟基查尔酮曼尼希碱类化合物、其制备方法和用途
NO300211B1 (no) Heterosykliske karboksylsyrer, farmasöytiske preparater og anvendelse av karboksylsyrene til fremstilling av preparatene
JPH09510222A (ja) ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
WO2014063587A1 (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
TW200951129A (en) Amide derivative and pharmaceutical composition comprising the same
WO2008062770A1 (fr) Dérivé de quinolone ou sel acceptable du point de vue pharmaceutique de celui-ci
CN110698411A (zh) 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
TWI229673B (en) Benzisoxazoles and phenones as alpha2-antagonists
US9434705B2 (en) L-setastine hydrochloride and preparation method thereof
US9242959B2 (en) (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
WO2019044940A1 (ja) 環状アミン誘導体及びその医薬用途
JPH11503128A (ja) 新規複素環式化合物
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
TW317565B (enExample)
WO1994008964A1 (fr) Derive de n-phenethylazepine et son utilisation
CZ296599B6 (cs) Hydrochlorid nebo fumarát 1-{2-[(2R)-(3,4-dichlorfenyl)-4-(3,4,5-trimethoxybenzoyl)morfolin-2-yl]ethyl}spiro[benzo(c)thiofen-1(3H),4'-piperidin]-(2S)-oxidu a prostredek ho obsahující
HK1154381A (en) Novel compounds active as muscarinic receptor antagonists
WO2013075624A1 (zh) 甘氨酸重摄取抑制剂及其应用
JP2014012641A (ja) 新規ピリジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150506

RJ01 Rejection of invention patent application after publication